Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Melanoma 236 Carcinoma, Non-Small-Cell Lung 78 Carcinoma, Renal Cell 61 Neoplasm Metastasis 52 Neoplasms 47 Prostatic Neoplasms 34 Uveal Melanoma 29 Lung Neoplasms 28 Pancreatic Neoplasms 27 Carcinoma, Hepatocellular 25 Brain Neoplasms 23 Sarcoma 22 Colorectal Neoplasms 21 Breast Neoplasms 20 Squamous Cell Carcinoma of Head and Neck 18 Small Cell Lung Carcinoma 18 Skin Neoplasms 17 Kidney Neoplasms 17 Diabetes Mellitus, Insulin-Dependent, 12 17 Carcinoma, Transitional Cell 17 Ovarian Neoplasms 15 Triple Negative Breast Neoplasms 14 Urinary Bladder Neoplasms 13 Mesothelioma 13 Uterine Cervical Neoplasms 12 Recurrence 12 Glioblastoma 12 Multiple Myeloma 11 Lymphoma 11 Clear-cell metastatic renal cell carcinoma 11

Interventions

pembrolizumab 3 Paclitaxel 2 relatlimab 1 nintedanib 1 lifileucel 1 dabrafenib 1 Vitamin D 1 Temozolomide 1 Surveys and Questionnaires 1 Opdualag 1 Nivolumab 1 Ipilimumab 1 Eye Movement Desensitization Reprocessing 1 Electrochemotherapy 1 Dacarbazine 1 Cholecalciferol 1 Carboplatin 1 Albumin-Bound Paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Melanoma, Cutaneous Malignant × Ipilimumab × Clear all

NCT06743126 2026-05-29

SUPRAME

Immatics US, Inc.

Phase 3 Recruiting

Melanoma, Cutaneous Malignant

Data powered by HemOnc (CC BY 4.0) Colophon ⚡